The effects of Atorvastatin (10 mg) on systemic inflammation in heart failure
The effects of Atorvastatin (10 mg) on systemic inflammation in heart failure
复制标题
DOI：
10.1016/j.amjcard.2005.07.092
复制
发表时间：
2005-12-15
影响因子：
2.8
通讯作者：
Levy, WC
中科院分区：
文献类型：
--
作者：
Mozaffarian, D;Minami, E;Levy, WC
在观察性研究中，他汀类药物与心力衰竭（HF）患者（包括非缺血性HF患者）的死亡率降低相关。这些益处可能与抗炎作用有关;然而，他汀类药物对HF全身炎症的影响尚未得到充分证实。我们进行了一项为期16周、单中心、随机、双盲、安慰剂对照、交叉临床试验，观察阿托伐他汀10 mg/天对22例纽约心脏协会II或III级症状、左心室射血分数为1.5%的HF患者（包括20例非缺血性HF）全身炎症标志物浓度的影响。
In observational studies, statins are associated with lower mortality in patients with heart failure (HF), including those with nonischemic HF. Such benefits could be related to anti-inflammatory effects; however, the effects of statins on systemic inflammation in HF are not well-established. We conducted a 16-week, single-center, randomized, double-blind, placebo-controlled, crossover clinical trial of the effects of atorvastatin 10 mg/day on concentrations of systemic inflammatory markers in 22 patients with HF (including 20 with nonischemic HF) with New York Heart Association class II or III symptoms and left ventricular ejection fraction of